ABCB1 haplotypes are associated with Pgp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib

Author：                    

Publisher： Spandidos Publications

ISSN： 1792-1074

Source： Oncology Letters, Vol.7, Iss.4, 2014-01, pp. : 1313-1319

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application

By Ghatnekar Ola   Hjalte Frida   Taylor Matthew  

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 851-858

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of Cytopenias Occurring in Imatinib Treated Chronic Myeloid Leukemia (CML) Patients

By Paul T.  

Indian Journal of Hematology and Blood Transfusion, Vol. 26, Iss. 2, 2010-06 ,pp. : 56-61

Springer Publishing Company

Access to resources Recommend Favorite

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 995-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

By Seong S. J.   Lim M.   Sohn S. K.   Moon J. H.   Oh S.-J.   Kim B. S.   Ryoo H. M.   Chung J. S.   Joo Y. D.   Bang S. M.   Jung C. W.   Kim D. H.   Park S. Y.   Yoon S. S.   Kim I.   Lee H. G.   Won J. H.   Min Y. H.   Cheong J. W.   Park J. S.   Eom K. S.   Hyun M. S.   Kim M. K.   Kim H.   Park M. R.   Park J.   Kim C. S.   Kim H. J.   Kim Y. K.   Park E. K.   Zang D. Y.   Jo D. Y.   Lee H. W.   Yoon Y.-R.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 756-760

Oxford University Press

Access to resources Recommend Favorite

Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients

By                    

Oncology Letters, Vol. 2, Iss. 1, 2011-01 ,pp. : 181-187

Spandidos Publications

Access to resources Recommend Favorite